New Perspectives on Inflammatory CNS Disease Therapies by Schmierer, K
New Perspectives on Inflammatory CNS Disease Therapies 
Klaus Schmierer 
This presentation will focus on the treatment of people with multiple sclerosis (pwMS) and 
clinically isolated syndrome (pwCIS), with some comments on neuromyelitis optica (NMO) 
and an emphasis on the role of repurposed drugs in the current and future management of 
people with these conditions.  The rising number of available disease modifying drugs 
(DMD) for people with relapsing MS (pwRMS) has expanded treatment options, however 
also increased the uncertainty about the best treatment strategy, particularly for colleagues 
who do not regularly see pwMS in their clinical practice.  Broadly speaking, there are two 
strategies for the use of DMD in pwRMS, early induction or escalation.  Assessing and 
explaining the benefit-risk balance of DMD are key for decision making, and to empower 
pwRMS to take such decisions jointly with their clinicians poses a major challenge.  Even 
within a seemingly unified healthcare system, such as the NHS in the UK, there is 
heterogeneity of what is considered ‘best practise’, and influenced by restrictions of access 
to DMD (an issue in many countries).  The question of whether or not to treat pwCIS 
depends on early signs of dissemination, in which case treatment should commence.  Whilst 
there is currently no licensed DMD for pwNMO, various immunomodulatory drugs are being 
used, and trials with promising molecules underway.  The debate whether trials should be 
placebo-controlled is ongoing.  With two exceptions all currently licensed (and some 
unlicensed) DMD used in pwCIS and pwMS are repurposed drugs, which have served pwMS 
well for over 20 years since the introduction of beta-interferons revolutionised MS 
management.  Whilst repurposed drugs are thus the mainstay of current MS disease 
modifying therapy, the more recent discussion about repurposing has focussed on generic 
drugs that may not only be safe and effective, but also more affordable treatments for 
pwMS. 
